During the cold winter months, many people notice their skin’s condition worsens. Dry air and indoor heating can exacerbate symptoms of eczema, or atopic dermatitis. This leads to dry, cracked ...

Topical pumecitinib 3% gel shows strong efficacy and good tolerability in mild-to-moderate atopic dermatitis. Explore the ...

The data showed a favourable safety and tolerability profile consistent with earlier Zoryve clinical trials.

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data ...

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.

To help you find the best eczema-friendly skin care products, I tapped several dermatologists for their insights and product recommendations.

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...